Abstract 4923
Background
Little is known about signaling pathway activity in esophageal adenocarcinomas. Using a new methodology we have delineated the activity of key pathways involved in tumor growth during neoadjuvant treatment. The aim is to use this knowledge to personalize, and thereby improve, treatment strategies.
Methods
We included all patients with esophageal adenocarcinomas between 2004 and May 2013 in the AMC. Paired tumor samples were obtained before start of neoadjuvant chemoradiation therapy according to the CROSS regimen and at surgical resection of the esophagus. Using a custom-built device, digital annotations of whole slide H&E scans were transferred to a hematoxylin-stained slide, which was subsequently deparaffinized. Marked tumor areas were scraped for RNA extraction and qPCR. qPCR data were subjected to stringent QC prior to determining the signaling pathway activity scores of the AR-, ER-, FOXO/PI3K-, HH-, TGF-β- and WNT pathway, using a combined mRNA-Bayesian model-based method (Verhaegh et al, Cancer Res, 2014). Pathway activity scores were correlated to pathological response to treatment (Mandard score).
Results
Based on a test set of esophageal tumor tissue samples, we determined that tumor areas of ≥ 2mm2 were eligible for RNA isolation and pathway activity analysis. We provide a analysis of 288 currently processed samples. FOXO activity was significantly higher in post-treatment resection specimen compared to matched pre-treatment biopsies (p < 0.001). Patients with high FOXO activity in post-treatment resection specimen showed better response to treatment (p = 0.019).
Conclusions
The assessment of pathway activity is feasible on small amounts of tumor. Marked dynamics in FOXO activity are observed during nCRT in esophageal adenocarcinomas. Patients with high FOXO activity post-nCRT show better response to treatment. An active PI3K pathway blocks FOXO transcriptional activity. To increase FOXO transcriptional activity, patients might benefit from the addition of PI3K-inhibitors to the nCRT regimen.
Clinical trial identification
Legal entity responsible for the study
AMC.
Funding
Royal Philips.
Editorial Acknowledgement
Disclosure
M. Stoffels, L. Holtzer, A. Van Brussel: Employee: Royal Philips; Research funding: Royal Philips. H. van Ooijen: Employee: Royal Philips; Patents, royalties or other intellectual property: Royal Philips. E.M.G. Aussems-Custers. A. van de Stolpe: Employee, Funded: Royal Philips. M. van Berge Henegouwen: Research funding: Olympus. M.F. Bijlsma: Research funding: Celgene. H.W.M. van Laarhoven: Consultant: Philips, Celgene, Lilly, Nordic; Unrestricted research funding: Philips, Bayer, BMS, Celgene, Lilly, Merck Serono, MSD, Nordic, Roche. All other authors have declared no conflicts of interest.
Resources from the same session
1159 - Molecular characterization and search for founding effects in Canarian families with Hereditary Breast and Ovarian Cancer Syndrome
Presenter: Elisenda Llabres Valenti
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3725 - Effect of the polymorphism rs2066844 of the NOD2 gene on colon cancer incidence in a high cardiovascular risk population. Modulation by gender
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3708 - Effect of the polymorphisms rs1476413, rs1801131, rs4846052 and rs6541003 of the MTHFR gene on prostate cancer in a high cardiovascular risk population
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5057 - Association of a genetic variant in cyclin-dependent kinase Inhibitor 2A gene with the increased risk of breast cancer
Presenter: Soodabeh Shahid Sales
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5970 - Investigating the role of HAT protein TIP60 in regulating functional dynamics of nuclear receptor PXR
Presenter: KARISHMA BAKSHI
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1360 - The role of downregulated SIRT3 expression in patients with hepatocellular carcinoma
Presenter: Hanhee Jo
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1634 - Prediction and Intervention of Colorectal Cancer Risk with Artificial Intelligent System
Presenter: Yang Ge
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4921 - Measuring the Efficiency of Cancer Care in Europe
Presenter: Rikard Althin
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1235 - Circulating cell-free DNA isolated from plasma of mesenteric veins predicts prognosis in stage II colorectal cancer patients
Presenter: Chih-Yung Yang
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5169 - _lonality of uterine carcinosarcoma as a factor of clinical prognosis.
Presenter: Natalia Levitskaya
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract